Receptor News and Research

RSS

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

NanoString Technologies, Inc.a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its 3D Biology™ portfolio with the commercial launch of the nCounter® PanCancer Profiles, seven new gene expression panels each designed to interrogate a focused area of cancer biology including immuno-oncology.

9 Nov 2015

Diabetes drug liraglutide ineffective in patients with advanced heart failure

In an attempt to correct defects in the energy generation that contributes to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure. Despite improvements in blood sugar control, the therapy did not improve the clinical stability or pumping action of the heart in patients with advanced heart failure.

9 Nov 2015

Combatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr Chakravarthy

Inhaled anesthetics are fairly common all over the world for minor and extensive surgical procedures in patients of all age groups. In the olden days when anesthesia was first developed, ether was the first inhaled anesthetic. That has been replaced, with the more recent discoveries of sevoflurane, isoflurane, and desflurane.

9 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

6 Nov 2015

Circulating protein predicts risk of chronic kidney disease

Make room, cholesterol. A new disease marker is entering the medical lexicon: suPAR, or soluble urokinase-type plasminogen activator receptor.

6 Nov 2015

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States.

6 Nov 2015

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

CytomX Therapeutics, a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies.

6 Nov 2015

Researchers identify new regulatory pathway that may play vital role in basal-like breast cancer

Researchers have identified a new regulatory pathway that may play an important role in basal-like breast cancer (BLBC), a particularly aggressive form of breast cancer often referred to as "triple negative." This pathway may serve as a target for the development of an effective therapeutic.

5 Nov 2015

Estrogen-like drug may not be beneficial to women with Alzheimer's dementia

An estrogen-like drug, raloxifene, has no demonstrated benefit on memory and thinking skills for women with dementia due to Alzheimer's disease, according to a study published in the November 4, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Nov 2015

CK5 protein marks ovarian cancer likely to be resistant to cisplatin

A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.

5 Nov 2015

International research project examines effectiveness of tried and tested medicines for different diseases

The Medical University of Vienna is coordinating an international research project, which investigates the effectiveness of tried and tested medicines for the treatment of some of the heaviest burdens of our modern society including diseases such as cancer, diabetes and cardiovascular diseases. One molecule that these disorders have in common is a receptor known as the calcium-sensing receptor (CaSR), which is the molecular starting point of this project.

4 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

Discovery offers promising alternative to current therapies for AMD and ROP

A research team led by scientists at Beth Israel Deaconess Medical Center and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal diseases.

3 Nov 2015

Rotation model provides explanation of ligand activation mechanism of dimeric receptors

"This 'rotation model', which made the cover of BioEssays, represents a true paradigm shift in the membrane receptor field," stated Prof. Pierre De Meyts, a renowned researcher of insulin and receptor binding for almost half a century and one of the reviewers of the paper by Prof. Ichiro Maruyama, the head of the Information Processing Biology Unit at Okinawa Institute of Science and Technology Graduate University.

31 Oct 2015

Gut bacteria may increase risk of metabolic syndrome

An excess of bacteria in the gut can change the way the liver processes fat and could lead to the development of metabolic syndrome, according to health researchers.

30 Oct 2015

Scientists one step closer to developing new treatment for inflammatory bowel disease

For patients with inflammatory bowel disease, the possibility of taking a single pill to bring long-lasting relief might seem too good to be true. Scientists at the Lewis Katz School of Medicine at Temple University are on the brink of making that happen, thanks to a recent proof-of-concept study, in which the severity of a form of inflammatory bowel disease in mice was dramatically reduced with one oral dose of a protein isolated from a bacterial biofilm.

30 Oct 2015

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Inc. announced today that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital.

30 Oct 2015

Adelaide researchers identify key protein involved in 'super-inflammatory' immune response

Researchers have made another important step in the progress towards being able to block the development of multiple sclerosis (MS) and other autoimmune diseases.

29 Oct 2015

Receptor News and Research

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

Diabetes drug liraglutide ineffective in patients with advanced heart failure

Combatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr Chakravarthy

Viralytics enters into clinical trial collaboration agreement with MSD

New tool could help identify patients most likely to benefit from chemoprevention

Circulating protein predicts risk of chronic kidney disease

Hutchison MediPharma begins sulfatinib Phase I trial in US

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

Researchers identify new regulatory pathway that may play vital role in basal-like breast cancer

Estrogen-like drug may not be beneficial to women with Alzheimer's dementia

CK5 protein marks ovarian cancer likely to be resistant to cisplatin

International research project examines effectiveness of tried and tested medicines for different diseases

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Discovery offers promising alternative to current therapies for AMD and ROP

Rotation model provides explanation of ligand activation mechanism of dimeric receptors

Gut bacteria may increase risk of metabolic syndrome

Scientists one step closer to developing new treatment for inflammatory bowel disease

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Adelaide researchers identify key protein involved in 'super-inflammatory' immune response

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News